News Detail

BUZZ-Zentalis Pharma gains as FDA lifts partial clinical hold on cancer drug studies

Reuters · 3d ago

Listen to the news

BUZZ-Zentalis Pharma gains as FDA lifts partial clinical hold on cancer drug studies

** Shares of drug developer Zentalis Pharmaceuticals ZNTL.O rise 45.68% to $4.72 premarket

** Co says U.S. FDA has lifted the partial clinical hold on studies of azenosertib, its experimental cancer drug

** In June, FDA placed three studies on partial clinical hold following the death of two trial participants

** FDA has cleared the way for resumption in enrollment for all ongoing studies, with no changes in the development plan; co resume activities as quickly as possible

** Azenosertib is currently being studied as monotherapy and combination studies in ovarian cancer and additional tumor types

** Up to last close, stock down ~79% YTD

(Reporting by Sriparna Roy in Bengaluru)

((Sriparna.Roy@thomsonreuters.com;))

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.

What's Trending

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.